Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reRNA-EGF vaccine
- Development stage
- Phase 1
- Lead developer
- Jiangsu Leeway Biological Technology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
The reRNA-EGF vaccine is an RNA-based therapeutic vaccine developed by Jiangsu Leeway Biological Technology Co.Ltd. It is designed to treat non-small cell lung cancer by inducing an immune response against Epidermal Growth Factor (EGF). The vaccine aims to generate antibodies that target and neutralize circulating EGF, thereby preventing it from binding to its receptor, Epidermal Growth Factor Receptor (EGFR), on cancer cells. This mechanism is intended to inhibit EGF-mediated signaling pathways that promote tumor cell proliferation, survival, and metastasis.
- Other names
- reRNA-EGF 疫苗
Beyond the preview
Go deeper on reRNA-EGF vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reRNA-EGF vaccine.